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Abstract
Objective: The objective of the present study was to assess the prevalence and
determinants of preconceptional folic acid supplement use among pregnant
women in Lebanon.
Design/setting/subjects: The study was a descriptive epidemiological study.
Analysis was performed on 5280 deliveries admitted to twelve member hospitals
of the National Collaborative Perinatal Neonatal Network during the period
September 2003–January 2005. Information on folic acid intake and maternal
and neonatal characteristics were obtained from obstetric charts along with direct
interviews performed by trained personnel. Logistic regression was performed to
determine the predictors of preconceptional folic acid use.
Results: The overall use of preconceptional folic acid supplementation was 14?0 %
(18?6 % in urban hospitals v. 2?7 % in rural hospitals). Higher socio-economic
status, lower parity and having a history of previous spontaneous abortions were
significantly associated with preconceptional folic acid use.
Conclusion: Our study shows that Lebanon currently has a low rate of pre-
conceptional folic acid supplement use. Intervention through the means of





Congenital anomalies affect an estimated 3% of newborns
worldwide. In the early 1990s, it ranked tenth on the list of
disability-adjusted life years lost in the Global Burden of
Disease Study(1). Nearly 50 years ago, it was found that the
B-vitamin folic acid plays a role in promoting normal
embryonic development(2). It was advised as a general
guideline that all females of childbearing age take a sup-
plement of 0?4mg folic acid to reduce the risk of congenital
malformations, including neural tube defects (NTD)(3).
Periconceptional supplementation with folic acid (before
conception and during the first 12 weeks of pregnancy)
was found to decrease the risk of NTD by 50–70%, while
also protecting from other birth defects such as those of the
heart, limbs, urinary tract, cleft lip and palate, as well as
other major structural abnormalities(4,5).
The 1990s and early 2000s witnessed an increase in the
worldwide use of periconceptional folic acid supple-
mentation as many developed countries promoted aware-
ness campaigns on the importance of folic acid. Increases in
the prevalence of periconceptional folic acid use were seen:
from 27% to 48% in the UK(6), from 5% to 36% in The
Netherlands(6), from 14% to 83% in Ireland(7), from 19% to
43% in Western Australia(8), from 32% to 40% in the USA(3)
and from 17% to 28% in Canada(9). Although these
improvements are notable, a large portion of pregnancies
remain unprotected. For the latter reason, folic acid for-
tification of staple foods (flour, breakfast cereals, etc.) has
begun in many countries such as Canada(9), Australia(10),
Germany(11), Chile(12), Costa Rica(13) and the USA(14). A 26%
reduction in NTD prevalence has been reported in the
USA since mandatory fortification(14). On the other hand,
researchers in other countries like Japan and Finland
have recently identified a possible need for intervention
because dietary folic acid intake is suspected to be
inadequate there(15,16).
Several studies have explored socio-economic corre-
lates of periconceptional folic acid use. Greater prob-
ability of supplement use has been associated with higher
socio-economic status, first pregnancies, maternal age
greater than 30 years, married status and non-smoking(17).
A recent study done in The Netherlands found that,
especially among women with a low level of education, a
diet low in folic acid was associated with increased risk of
giving birth to a child with a congenital heart defect(18).
In the Middle East region, there are very few data
available on preconceptional and periconceptional use of
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folic acid. A study done in Israel following a national
awareness campaign showed that preconceptional folic
acid use was 5?2 % before the campaign, increasing to
30?5 % after the intervention(19). Positive associations
were found between folic acid utilization, increasing
years of education and older age(19). Using a small and
selective sample, a study carried out in the United Arab
Emirates (UAE) found the prevalence of periconceptional
folic acid use to be 45 % and associated with higher
education and being of non-UAE nationality(20).
In Lebanon, there is no national policy about folic acid
fortification or supplement intake; the practice is left
to the individual physician’s judgement. Furthermore,
no studies have yet been done to determine the prev-
alence of preconceptional folic acid use. Such a study is
a mandatory step for an intervention awareness pro-
gramme if one is to be implemented. The objective of the
present study was to assess the prevalence and determine
the predictors of preconceptional folic acid use among
pregnant women in Lebanon.
Methods
The National Collaborative Perinatal Neonatal Network
(NCPNN), established in 1998, is a voluntary collaborative
network of professionals from different health-care insti-
tutions in Lebanon aiming to improve the health of
pregnant women and their newborns through quality
scientific research. The NCPNN has formed an integrated
perinatal neonatal database covering deliveries at major
hospitals throughout Lebanon. These hospitals are
believed to be representative of Lebanese hospital deliv-
eries but not of home deliveries, which are relatively low
in prevalence (12 %)(21). Data for the NCPNN database are
collected and documented by trained nurses, midwives
and research assistants using standardized questionnaires,
approved by the Institutional Research Board. The
questionnaires include items that cover parental socio-
demographic characteristics as well as maternal and
newborn health characteristics.
During the period September 2003 to January 2005 and
according to the Central Administration for Statistics
(Lebanese government statistical base), there were 98 766
births in Lebanon. During this period, the NCPNN was
selecting a random sample of newborns admitted to the
normal nursery at each hospital by selecting every con-
secutive fifth case. The present study was a descriptive
epidemiologic study that considered all live-born new-
borns admitted to the normal nursery and selected by
the NCPNN during this time period. The resulting sample
size was 7384 delivered newborns.
The sources of data used for the present study were:
(i) direct interviews with mothers conducted after delivery
and before hospital discharge; and (ii) review of obstetric
charts. Socio-economic variables considered for the present
study included maternal and paternal education, monthly
household income, mode of hospital payment, class of
admission and hospital region. Maternal characteristics
included were maternal age at marriage, first pregnancy
and current delivery, parity, gravidity and smoking
behaviour. Obstetric and neonatal complications were
defined as past or present births with congenital mal-
formations, previous spontaneous abortions, and preg-
nancy complication. Questions involving folic acid
supplement use were incorporated in the NCPNN ques-
tionnaire over the study period and collected by direct
interviews. The questions elicited information on regular
folic acid intake before pregnancy, regular folic acid
intake after pregnancy, folic acid intake with or without
vitamin supplement, and folic acid subscriber (physician,
pharmacist, self). No information was collected as to the
specific timing at which folic acid was taken before
pregnancy. The subjects were asked about the brand of
folic acid supplements they took and the number of
tablets. However, the majority (more than 75 %) of the
subjects who did consume preconception folic acid had
missing information on the brand and/or the number of
tablets consumed; and hence information on dose is not
reported in the study. For the sake of the present study a
question asking whether the current pregnancy was
planned was added to the original questionnaire six
months after the study was initiated.
Odds ratios and 95% confidence intervals were calcu-
lated to assess the relationship between preconceptional
folic acid use and all socio-economic variables, maternal
characteristics, and obstetric and neonatal complications.
The OR and 95% CI reported are based on a logistic
regression model where the dependent variable was pre-
conceptional folic acid supplement use and the indepen-
dent variables were the above-mentioned socio-economic,
maternal, obstetric and neonatal characteristics that were
significant at the bivariate analysis (crude analysis).
Results
Of the 7348 women selected for the study, 5280 (71?9 %)
had information on preconceptional folic acid intake and
hence analysis was limited to this group. The average
age at delivery of the 5280 women included was 29?2
(SD 5?6) years, with 1739 (33?0 %) of the women being
primigravidae. A total of 3512 (69?8 %) of the women had
their pregnancies previously planned, out of the patients
for whom such information was available. Among pri-
migravidae, 83?1 % of the pregnancies were planned
with the average length of time between marriage and
first pregnancy being 1?3 (SD 1?3) years. Of the women
delivering in the participating hospitals, 3753 (71?1 %)
delivered in urban v. 1527 (28?9 %) in rural hospitals.
The prevalence of preconceptional folic acid use was
14?0 %: 18?6 % for women delivering in urban hospitals
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and 2?7 % for women delivering in rural setting hospitals.
The frequency of women taking preconceptional folic
acid in a multivitamin supplement was 4?3 % (n 226),
while 10?0 % (n 526) were taking folic acid as a separate
supplement. Physicians were the primary prescribers,
with 92?3 % of the women taking preconceptional folic
acid having had it recommended by a physician.
Table 1 shows the relationship between different
characteristics and folic acid supplement use pre-
conceptionally at the bivariate level. Preconceptional folic
acid intake was found to be positively associated with
socio-economic characteristics, measured as maternal and
paternal education, monthly household income, private
health insurance as mode of payment, urban setting
hospitals and first class admissions (all P5 0?000).
Maternal characteristics positively associated with pre-
conceptional folic acid intake included older maternal
age at marriage, first and current delivery, lower parity
levels, and not smoking during pregnancy (all P5 0?000).
Complications during pregnancy (P5 0?019) and history
of previous spontaneous abortions (P5 0?000) were also
positively associated with preconceptional folic acid
supplement use. Although women with a previous infant
with congenital malformations had higher folic acid
intake, the association did not reach statistical significance
(P5 0?234).
Results of the logistic regression model (Table 2)
showed that mothers delivering in urban hospitals were
more likely to use preconceptional folic acid than those
delivering in rural hospitals (P, 0?01). Higher monthly
household income and higher education significantly
predicted preconceptional folic acid use (all P, 0?01).
Similarly, private mode of payment (P5 0?02) and higher
class of admission (P5 0?03) were other socio-economic
status indicators associated with improved folic acid
intake. Lower parity was significantly associated with
positive preconceptional folic acid use (P5 0?04) and
mothers who had experienced previous spontaneous
abortions had greater probability of having taken pre-
conceptional folic acid (P, 0?01).
Discussion
Although it has been widely advised that all women of
childbearing age take 0?4 mg folic acid daily at least one
month prior to conception and throughout the first tri-
mester of pregnancy to decrease the risk of congenital
malformations including NTD(22–24), prevalence of intake
of preconceptional folic acid in Lebanon was found
to be 14?0 %, with 18?6 % prevalence in urban setting
hospitals and 2?7 % in rural setting hospitals, an issue that
needs to be given prompt attention. Preconceptional
folic acid intake was found to increase as socio-economic
conditions improved. Furthermore, certain maternal
characteristics and obstetric and neonatal complications
were also found to be associated with preconceptional
folic acid intake.
Preconceptional folic acid intake in Lebanon, in com-
parison with the current 48 % in the UK(6), 36 % in The
Netherlands(6), 83 % in Ireland(7) and 40 % in the USA(3),
was found to be markedly low at 14 %. It is important to
note, however, that these countries have targeted women
of childbearing age through national health awareness
programmes that have been implemented since the mid-
1990s. In other countries with minimal or no national
awareness campaigns conducted thus far, such as France,
Spain, Germany and Italy, prevalence of periconceptional
folic acid intake ranges from 1 % to 4?5 %(25). The pre-
valence of periconceptional folic acid in the UAE(20), a
country with a somewhat similar culture to Lebanon, was
found to be 45?5 %, yet the generalizability of that study
is questionable owing to the convenience sample of
hospitals selected and the small sample size (n 336) of the
participants included.
Similar to other studies(3,17,26), the present study
showed that socio-economic status, measured through
several indicators such as household monthly income,
maternal education, mode of payment and class of
admission, was associated with preconceptional folic acid
supplement use. This is probably due to more awareness
of the importance of and accessibility to antenatal and
inter-pregnancy care. Mothers delivering in urban setting
hospitals were also found to be at higher odds of using
preconceptional folic acid than those delivering in rural
hospitals, similar to a study that concluded that under-
privileged communities were less likely to use pre-
conceptional folic acid than their counterparts(22). A
possible explanation is more active continuing education
on the part of physicians participating in hospitals in
urban settings. A study done in Thailand, however, found
that the media was an important source of information on
the importance of folic acid(23). Primiparity was positively
associated with preconceptional folic acid use, as
found elsewhere in the literature(20).
Similar to other studies, a significant association was
noted between preconceptional folic acid intake and a
history of spontaneous abortions(27). One possible
explanation is that mothers with previous complications
had received folic acid as part of postpartum care to
decrease the risk of complications in future or current
pregnancies.
A limitation faced by the majority of such descriptive
epidemiological studies is the possibility of recall bias
occurring in respect to timing of folic acid tablet intake,
especially as it is dependent on determining the onset of
pregnancy(6). Another bias that might have influenced the
present results is the mistaking of folic acid for other
multivitamin/mineral supplementation, such as iron
tablets. However, most multivitamins sold in Lebanon,
including iron tablets, contain the required amount of
folic acid in their composition. On the other hand, the
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Table 1 Bivariate analysis characterizing preconceptional folic acid intake among Lebanese women, September 2003–January 2005
Folic acid before pregnancy
Total Yes
n %* n %- OR 95 % CI P
Socio-economic characteristics
Maternal education
Illiterate/Elementary 763 14?8 22 2?9 1?0 Reference
Intermediate 1045 20?3 59 5?6 2?0 1?2, 3?3
Secondary/Technical 1463 28?4 124 8?5 3?1 2?0, 5?0
University 1880 36?5 512 27?2 12?6 8?2, 19?5 0?000
Paternal education
Illiterate/Elementary 940 18?5 28 3?0 1?0 Reference
Intermediate 989 19?5 56 5?7 2?0 1?2, 3?1
Secondary/Technical 1247 24?6 119 9?5 3?4 2?3, 5?2
University 1902 37?5 511 26?9 12?0 8?1, 17?7 0?000
Monthly household income ($)
300–499 873 17?4 37 4?2 1?0 Reference
500–1499 1626 32?5 147 9?0 2?2 1?6, 3?3
1500–2999 758 15?1 233 30?7 10?0 7?0, 14?4
.3000 229 4?6 138 60?3 34?3 22?5, 52?3
No information 1522 30?4 144 9?5 2?4 1?6, 3?4 0?000
Hospital region
Urban 3753 71?1 697 18?6 8?3 6?0, 11?4
Rural 1527 28?9 41 2?7 1?0 Reference 0?000
Mode of payment
Self 436 9?1 48 10?4 1?8 1?3, 2?6
Insurance company 1799 35?2 487 27?1 5?8 4?9, 7?0
Others 2874 55?7 170 6?0 1?0 Reference 0?000
Class of admission
1st 1323 27?4 446 33?7 7?5 6?1, 9?2
2nd 1421 29?4 133 9?4 1?5 1?2, 2?0
3rd 2091 43?2 133 6?4 1?0 Reference 0?000
Maternal characteristics
Age at current delivery
#24 years 1170 22?3 68 5?8 1?0 Reference
25–29 years 1583 30?2 236 14?9 2?8 2?1, 3?8
$30 years 2494 47?5 428 17?2 3?4 2?6, 4?4 0?000
Age at marriage
#24 years 2914 56?0 242 8?3 1?0 Reference
25–29 years 1545 29?7 313 20?3 2?8 2?3, 3?4
$30 years 748 14?4 172 23?0 3?3 2?7, 4?1 0?000
Age at first pregnancy
#24 years 2411 48?2 154 6?4 1?0 Reference
25–29 years 1588 31?7 306 19?3 3?5 2?8, 4?3
$30 years 1003 20?1 206 20?5 3?8 3?0, 4?7 0?000
Smoking during pregnancy
No 4664 89?8 686 14?7 2?3 1?6, 3?2
Yes 529 10?2 37 7?0 1?0 Reference 0?000
Gravidity
1 1739 33?0 239 13?7 1?0 0?8, 1?1
$2 3527 67?0 498 14?1 1?0 Reference 0?736
Parity
0 2063 39?2 338 16?4 3?1 2?2, 4?4
1–2 2536 48?2 360 14?2 2?7 1?9, 3?7
$3 665 12?6 39 5?9 1?0 Reference 0?000
Obstetric and neonatal complications
Pregnancy complications
No 3443 65?7 455 13?2 1?0 Reference
Yes 1801 34?3 281 15?6 1?2 1?0, 1?4 0?019
Previous spontaneous abortion
No 3990 76?7 499 12?5 1?0 Reference
Yes 1213 23?3 232 19?1 1?7 1?4, 2?0 0?000
Previous infant with congenital malformation
No 5158 98?6 714 13?8 1?0 Reference
Yes 74 1?4 14 18?9 1?5 0?8, 2?6 0?234
*Column percentage.
-Row percentage.
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main reason behind the relatively high rate of missing
information on folic acid intake (30 %) is that, as men-
tioned earlier, data on folic acid were obtained through
direct interview with mothers. Depending on the work-
load in the delivery suite and nursery, data collectors
might drop the whole interview with the mother,
including information on folic acid.
Conclusion
According to the results of the present study, Lebanon
currently has a low rate of preconceptional folic acid
supplement use. A national intervention programme
emphasizing the importance of preconceptional folic acid
use would be ideal in the Lebanese public health setting.
Due to social and religious factors, nearly all pregnancies
in Lebanon occur following wedlock, where obligatory
premarital blood tests are done before a marriage certi-
ficate can be obtained. Awareness at this stage, possibly
achieved through the distribution of brochures in medical
laboratories, would be both a low-cost and efficient
method of raising public knowledge. It is believed that such
an intervention would be effective because the average
length of time between marriage and first pregnancy was
found to be 1?3 years, and hence information provided at
the time of marriage could still be remembered.
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